Literature DB >> 15308713

Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.

Lakshmi Ramakrishna1, Krishnamurthy Kumar Anand, Kumarasamypet M Mohankumar, Udaykumar Ranga.   

Abstract

DNA vaccines have been successful in eliciting potent immune responses in mice. Their efficiency, however, is restricted in larger animals. One reason for the limited performance of the DNA vaccines is the lack of molecular strategies to enhance immune responses. Additionally, genes directly cloned from pathogenic organisms may not be efficiently translated in a heterologous host expression system as a consequence of codon bias. To evaluate the influence of codon optimization on the immune response, we elected to use the Tat antigens of human immunodeficiency virus type 1 (HIV-1) (subtype C) and HIV-2, as these viral antigens are poorly immunogenic in natural infection and in experimental immunization and they are functionally important in viral infectivity and pathogenesis. Substituting codons that are optimally used in the mammalian system, we synthetically assembled Tat genes and compared them with the wild-type counterparts in two different mouse strains. Codon-optimized Tat genes induced qualitatively and quantitatively superior immune responses as measured in a T-cell proliferation assay, enzyme-linked immunospot assay, and chromium release assay. Importantly, while the wild-type genes promoted a mixed Th1-Th2-type cytokine profile, the codon-optimized genes induced a predominantly Th1 profile. Using a pepscan strategy, we mapped an immunodominant T-helper epitope to the core and basic domains of HIV-1 Tat. We also identified cross-clade immune responses between HIV-1 subtype B and C Tat proteins mapped to this T-helper epitope. Developing molecular strategies to optimize the immunogenicity of DNA vaccines is critical for inducing strong immune responses, especially to antigens like Tat. Our identification of a highly conserved T-helper epitope in the first exon of HIV-1 Tat of subtype C and the demonstration of a cross-clade immune response between subtypes B and C are important for a more rational design of an HIV vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308713      PMCID: PMC506957          DOI: 10.1128/JVI.78.17.9174-9189.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  107 in total

Review 1.  DNA vaccines: immunology, application, and optimization*.

Authors:  S Gurunathan; D M Klinman; R A Seder
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus.

Authors:  R Stratford; G Douce; L Zhang-Barber; N Fairweather; J Eskola; G Dougan
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

3.  Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains.

Authors:  G Goldstein; G Tribbick; K Manson
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

Review 4.  From the outside in: extracellular activities of HIV Tat.

Authors:  D Noonan; A Albini
Journal:  Adv Pharmacol       Date:  2000

5.  Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1.

Authors:  H Xiao; C Neuveut; H L Tiffany; M Benkirane; E A Rich; P M Murphy; K T Jeang
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

6.  Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.

Authors:  S Corbet; L Vinner; D M Hougaard; K Bryder; H V Nielsen; C Nielsen; A Fomsgaard
Journal:  AIDS Res Hum Retroviruses       Date:  2000-12-10       Impact factor: 2.205

7.  Efficient vaccination by intradermal or intramuscular inoculation of plasmid DNA expressing hepatitis B surface antigen under desmin promoter/enhancer control.

Authors:  M Kwissa; v K von Kampen; R Zurbriggen; R Glück; J Reimann; R Schirmbeck
Journal:  Vaccine       Date:  2000-05-08       Impact factor: 3.641

8.  Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.

Authors:  T M Allen; D H O'Connor; P Jing; J L Dzuris; B R Mothé; T U Vogel; E Dunphy; M E Liebl; C Emerson; N Wilson; K J Kunstman; X Wang; D B Allison; A L Hughes; R C Desrosiers; J D Altman; S M Wolinsky; A Sette; D I Watkins
Journal:  Nature       Date:  2000-09-21       Impact factor: 49.962

9.  Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.

Authors:  B Ensoli; A Cafaro
Journal:  J Biol Regul Homeost Agents       Date:  2000 Jan-Mar       Impact factor: 1.711

10.  Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.

Authors:  C D Pauza; P Trivedi; M Wallace; T J Ruckwardt; H Le Buanec; W Lu; B Bizzini; A Burny; D Zagury; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  22 in total

1.  Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.

Authors:  Shixia Wang; Jessica Taaffe; Christopher Parker; Alicia Solórzano; Hong Cao; Adolfo García-Sastre; Shan Lu
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

2.  Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.

Authors:  Benson Y H Cheng; Aitor Nogales; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  Virology       Date:  2016-11-14       Impact factor: 3.616

3.  Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.

Authors:  Yiling Zhang; Liqiang Feng; Liang Li; Dimin Wang; Chufang Li; Caijun Sun; Pingchao Li; Xuehua Zheng; Yichu Liu; Wei Yang; Xuefeng Niu; Nanshan Zhong; Ling Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Protection of chickens against avian influenza with non-replicating adenovirus-vectored vaccine.

Authors:  Haroldo Toro; De-chu C Tang; David L Suarez; Jianfeng Zhang; Zhongkai Shi
Journal:  Vaccine       Date:  2008-03-17       Impact factor: 3.641

5.  Comparative study of synonymous codon usage variations between the nucleocapsid and spike genes of coronavirus, and C-type lectin domain genes of human and mouse.

Authors:  Insung Ahn; Byeong-Jin Jeong; Hyeon Seok Son
Journal:  Exp Mol Med       Date:  2009-10-31       Impact factor: 8.718

Review 6.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

7.  DNA immunization with plasmids encoding fusion and nucleocapsid proteins of bovine respiratory syncytial virus induces a strong cell-mediated immunity and protects calves against challenge.

Authors:  Mathieu Boxus; Marylène Tignon; Stefan Roels; Jean-François Toussaint; Karl Walravens; Marie-Ange Benoit; Philippe Coppe; Jean-Jacques Letesson; Carine Letellier; Pierre Kerkhofs
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

8.  Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses.

Authors:  Elena Carnero; Wenjing Li; Antonio V Borderia; Bruno Moltedo; Thomas Moran; Adolfo García-Sastre
Journal:  J Virol       Date:  2008-11-12       Impact factor: 5.103

9.  Translational control of recombinant human acetylcholinesterase accumulation in plants.

Authors:  Brian C Geyer; Samuel P Fletcher; Tagan A Griffin; Michael J Lopker; Hermona Soreq; Tsafrir S Mor
Journal:  BMC Biotechnol       Date:  2007-05-30       Impact factor: 2.563

10.  DNA vaccines: designing strategies against parasitic infections.

Authors:  Catherine Ivory; Kris Chadee
Journal:  Genet Vaccines Ther       Date:  2004-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.